REGN
Regeneron Pharmaceuticals, Inc. NASDAQ Listed Apr 2, 1991$609.94
+0.33%
vs $607.93
Mkt Cap $62.8B
52w Low $506.38
32.9% of range
52w High $821.11
50d MA $680.04
200d MA $697.07
P/E (TTM)
14.7x
EV/EBITDA
10.2x
P/B
2.0x
Debt/Equity
0.1x
ROE
14.1%
P/FCF
16.2x
RSI (14)
47.90
ATR (14)
$15.75
Beta
0.40
50d MA
$680.04
200d MA
$697.07
Avg Volume
1.2M
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
777 Old Saw Mill River Road · Tarrytown, NY 10591-6707 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 8.91 | 9.47 | +6.3% | 686.36 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% | — |
| Jan 30, 2026 | TNS | 10.74 | 11.44 | +6.5% | 741.45 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% | — |
| Oct 28, 2025 | TNS | 9.65 | 11.83 | +22.6% | 654.48 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% | — |
| Aug 1, 2025 | TNS | 8.43 | 12.89 | +52.9% | 558.87 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% | — |
| Apr 29, 2025 | TNS | 8.62 | 8.22 | -4.6% | 568.91 | +1.8% | +5.2% | -1.5% | +2.6% | -0.3% | -7.5% | — |
| Feb 4, 2025 | TNS | 11.21 | 12.07 | +7.7% | 697.05 | +1.7% | +2.8% | +0.7% | -1.7% | -2.8% | -3.6% | — |
| Oct 31, 2024 | TNS | 11.69 | 12.46 | +6.6% | 838.20 | +0.8% | +0.6% | -1.7% | +0.1% | -1.5% | +1.0% | — |
| Aug 1, 2024 | TNS | 10.61 | 11.56 | +9.0% | 1093.14 | +0.6% | -1.0% | -1.0% | -0.5% | +0.2% | +4.3% | — |
| May 2, 2024 | TNS | 10.17 | 9.55 | -6.1% | 937.61 | -1.1% | +2.1% | +0.2% | +1.2% | -1.5% | +1.3% | — |
| Feb 2, 2024 | TNS | 10.73 | 11.86 | +10.5% | 945.18 | -1.4% | -0.9% | +0.2% | +0.1% | +0.8% | +0.7% | — |
| Nov 2, 2023 | TNS | 10.72 | 11.59 | +8.1% | 818.79 | +2.4% | -0.2% | +1.9% | -0.2% | -1.0% | -2.7% | — |
| Aug 3, 2023 | TNS | 9.84 | 10.24 | +4.1% | 771.45 | +0.6% | -0.6% | +1.1% | +0.7% | +0.7% | +0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 18 | Leerink Partners | Downgrade | Outperform → Market Perform | $641 | $698.25 | $615.93 | -11.8% | -9.8% | +0.1% | +3.1% | -1.1% | -0.6% |
| May 18 | Citigroup | Downgrade | Buy → Neutral | $700 | $698.25 | $615.93 | -11.8% | -9.8% | +0.1% | +3.1% | -1.1% | -0.6% |
| May 1 | Guggenheim | Maintains | Buy → Buy | — | $707.06 | $703.02 | -0.6% | -0.8% | +1.1% | -1.0% | +2.7% | -1.7% |
| Apr 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $686.36 | $693.08 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% |
| Apr 30 | Barclays | Maintains | Overweight → Overweight | — | $686.36 | $693.08 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% |
| Apr 30 | Truist | Maintains | Buy → Buy | — | $686.36 | $693.08 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% |
| Apr 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $686.36 | $693.08 | +1.0% | +3.0% | -0.8% | +1.1% | -1.0% | +2.7% |
| Apr 23 | TD Cowen | Maintains | Buy → Buy | — | $746.58 | $750.99 | +0.6% | +2.6% | -1.9% | -0.9% | -1.7% | -6.2% |
| Apr 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $746.58 | $750.99 | +0.6% | +2.6% | -1.9% | -0.9% | -1.7% | -6.2% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $767.85 | $771.48 | +0.5% | -2.5% | -0.3% | +1.2% | -0.2% | -1.1% |
| Apr 8 | Bernstein | Maintains | Outperform → Outperform | — | $760.27 | $765.26 | +0.7% | +2.0% | -1.0% | -2.5% | -0.3% | +1.2% |
| Mar 31 | Truist | Maintains | Buy → Buy | — | $749.29 | $757.47 | +1.1% | +3.1% | +0.6% | -2.0% | +0.2% | -0.4% |
| Mar 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $781.67 | $771.10 | -1.4% | +1.2% | -3.1% | +2.7% | -2.9% | -0.7% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $785.51 | $783.17 | -0.3% | -0.7% | -3.3% | +3.2% | +0.6% | +2.5% |
| Feb 2 | Truist | Maintains | Buy → Buy | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | JP Morgan | Maintains | Overweight → Overweight | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Feb 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $741.45 | $732.92 | -1.2% | +1.8% | +0.6% | +2.1% | -1.1% | +2.5% |
| Jan 22 | Evercore ISI | Maintains | Outperform → Outperform | — | $749.33 | $750.34 | +0.1% | +0.8% | -0.3% | +1.2% | +1.1% | -2.6% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $812.27 | $805.81 | -0.8% | -1.4% | -0.6% | -3.6% | -1.2% | -0.6% |
| Jan 7 | BofA Securities | Upgrade | Underperform → Buy | — | $776.54 | $786.18 | +1.2% | +4.6% | -1.4% | -0.6% | -3.6% | -1.2% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $746.80 | $741.59 | -0.7% | -0.7% | +1.5% | -0.8% | +0.5% | -0.1% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $692.58 | $695.06 | +0.4% | +4.9% | +2.8% | -0.7% | +1.5% | -0.8% |
| Dec 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $723.67 | $732.45 | +1.2% | -0.1% | -0.6% | -2.1% | -1.5% | +4.9% |
| Dec 4 | BMO Capital | Maintains | Outperform → Outperform | — | $723.67 | $732.45 | +1.2% | -0.1% | -0.6% | -2.1% | -1.5% | +4.9% |
| Dec 3 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $742.00 | $730.36 | -1.6% | -2.5% | -0.1% | -0.6% | -2.1% | -1.5% |
| Nov 24 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $755.90 | $759.05 | +0.4% | +0.7% | +3.4% | -0.3% | -0.6% | -3.9% |
| Nov 20 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $702.75 | $725.00 | +3.2% | +4.9% | +2.6% | +0.7% | +3.4% | -0.3% |
| Nov 7 | UBS | Maintains | Neutral → Neutral | — | $646.87 | $650.35 | +0.5% | +1.6% | -0.4% | +3.0% | +1.1% | +1.9% |
| Oct 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | BofA Securities | Maintains | Underperform → Underperform | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | Guggenheim | Maintains | Buy → Buy | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $654.48 | $650.41 | -0.6% | -0.2% | +0.2% | -0.3% | -1.5% | -2.2% |
| Oct 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $584.74 | $579.68 | -0.9% | -1.5% | +0.4% | +1.3% | +11.8% | -0.2% |
| Oct 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $557.73 | $556.92 | -0.1% | +2.7% | +0.7% | -1.3% | +1.6% | -0.2% |
| Oct 13 | Citigroup | Maintains | Buy → Buy | — | $564.63 | $551.50 | -2.3% | -1.2% | +2.7% | +0.7% | -1.3% | +1.6% |
| Oct 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $569.90 | $569.29 | -0.1% | -0.9% | -1.2% | +2.7% | +0.7% | -1.3% |
| Oct 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $583.24 | $584.01 | +0.1% | -3.3% | +1.1% | -0.9% | -1.2% | +2.7% |
| Aug 27 | Jefferies | Maintains | Buy → Buy | — | $587.65 | $591.87 | +0.7% | -0.1% | -1.3% | +0.2% | -0.5% | -2.4% |
| Aug 27 | Bernstein | Maintains | Outperform → Outperform | — | $587.65 | $591.87 | +0.7% | -0.1% | -1.3% | +0.2% | -0.5% | -2.4% |
| Aug 11 | Truist | Maintains | Buy → Buy | — | $563.00 | $561.52 | -0.3% | -3.0% | +1.9% | +0.9% | +0.8% | +2.6% |
| Aug 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $558.87 | $566.98 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% |
| Aug 4 | BMO Capital | Maintains | Outperform → Outperform | — | $558.87 | $566.98 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% |
| Aug 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $558.87 | $566.98 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% |
| Aug 4 | Guggenheim | Maintains | Buy → Buy | — | $558.87 | $566.98 | +1.5% | +2.3% | -0.3% | -2.6% | +0.8% | +0.6% |
| Jul 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $560.93 | $568.12 | +1.3% | +2.0% | -1.4% | -0.3% | -0.8% | -0.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 1 | $712.09 | $712 | 17,505 | -0.98% | -0.30% |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 2 | $710.87 | $1K | 17,511 | -0.98% | -0.30% |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 6 | $709.45 | $4K | 17,513 | -0.98% | -0.30% |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 4 | $707.40 | $3K | 17,519 | -0.98% | -0.30% |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 7 | $706.74 | $5K | 17,523 | -0.98% | -0.30% |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 14 | $705.56 | $10K | 17,530 | -0.98% | -0.30% |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 24 | $703.46 | $17K | 17,559 | -0.98% | -0.30% |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 15 | $702.46 | $11K | 17,583 | -0.98% | -0.30% |
| May 1, 2026 | RYAN ARTHUR FDir | — | Sell | 5 | $701.76 | $4K | 17,598 | -0.98% | -0.30% |
8-K
CytomX Therapeutics, Inc. -- 8-K Filing
Jun 3
8-K
Unknown — 8-K Filing
This boilerplate 8-K filing contains only standard legal disclaimers and forward-looking statement warnings, providing no material information about Regeneron's business operations or financial performance that would impact stock valuation.
Apr 8
8-K
Opko Health Inc. -- 8-K Filing
OPKO Health reported fourth-quarter 2025 results and is hosting a conference call to discuss financial performance and business developments with investors.
Feb 26
8-K · 5.02
!!! Very High
AtaiBeckley Inc. -- 8-K 5.02: Executive Change
AtaiBiomedicines appointed Michael Faerm as CFO and principal accounting officer, strengthening financial leadership amid the company's clinical development programs.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 6,654,913 | $5.1B | New | Mar 2026 |
| 2 | Dodge & Cox | 4,458,238 | $3.4B | Reduced | Mar 2026 |
| 3 | Jpmorgan Chase & Co | 4,311,806 | $3.2B | Added | Mar 2026 |
| 4 | Morgan Stanley | 2,778,646 | $2.1B | Reduced | Dec 2025 |
| 5 | Franklin Resources Inc | 2,722,071 | $2.1B | Added | Mar 2026 |
| 6 | Nuveen, Llc | 2,065,064 | $1.6B | Added | Mar 2026 |
| 7 | Invesco Ltd. | 1,724,478 | $1.3B | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 1,720,774 | $1.3B | New | Mar 2026 |
| 9 | Fmr Llc | 1,518,192 | $1.2B | Reduced | Mar 2026 |
| 10 | Capital World Investors | 1,419,000 | $1.1B | Added | Mar 2026 |
| 11 | Aqr Capital Management Llc | 1,231,008 | $946M | Added | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 1,189,584 | $919M | Added | Mar 2026 |
| 13 | Amundi | 1,009,798 | $780M | New | Mar 2026 |
| 14 | Northern Trust Corp | 941,941 | $728M | — | Mar 2026 |
| 15 | Two Sigma Investments, Lp | 812,236 | $628M | Added | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 765,411 | $591M | — | Mar 2026 |
| 17 | Bnp Paribas Financial Markets | 448,371 | $346M | Added | Mar 2026 |
| 18 | Neuberger Berman Group Llc | 427,129 | $330M | Added | Mar 2026 |
| 19 | National Pension Service | 371,551 | $287M | Added | Mar 2026 |
| 20 | Pictet Asset Management Holding Sa | 367,870 | $285M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Dodge & Cox Stock Fund | 2,908,804 | $2.2B | Mar 2026 |
| 2 | Fidelity 500 Index Fund | 1,282,577 | $1.0B | Feb 2026 |
| 3 | iShares Core S&P 500 ETF | 1,296,727 | $1.0B | Mar 2026 |
| 4 | Putnam Large Cap Value Fund | 1,082,054 | $802M | Jan 2026 |
| 5 | VANGUARD WELLINGTON FUND | 803,715 | $628M | Feb 2026 |
| 6 | iShares Biotechnology ETF | 758,232 | $586M | Mar 2026 |
| 7 | Invesco NASDAQ 100 ETF | 392,907 | $307M | Feb 2026 |
| 8 | JPMorgan U.S. Equity Fund | 336,504 | $260M | Mar 2026 |
| 9 | VANGUARD HEALTH CARE FUND | 318,062 | $236M | Jan 2026 |
| 10 | Pacer US Cash Cows 100 ETF | 302,012 | $224M | Jan 2026 |
| 11 | Dodge & Cox Global Stock Fund | 281,552 | $218M | Mar 2026 |
| 12 | JPMorgan Nasdaq Equity Premium Income ETF | 265,326 | $205M | Mar 2026 |
| 13 | Strategic Advisers U.S. Total Stock Fund | 235,050 | $184M | Feb 2026 |
| 14 | Dodge & Cox Balanced Fund | 221,300 | $171M | Mar 2026 |
| 15 | Schwab S&P 500 Index Fund | 225,967 | $168M | Jan 2026 |
| 16 | Ultra Fund | 225,000 | $167M | Jan 2026 |
| 17 | State Street(R) SPDR(R) Portfolio S&P 500(R) ETF | 211,946 | $164M | Mar 2026 |
| 18 | Invesco S&P 500 Equal Weight ETF | 219,216 | $163M | Jan 2026 |
| 19 | Schwab U.S. Large-Cap Growth ETF | 193,316 | $151M | Feb 2026 |
| 20 | Putnam Focused Large Cap Value ETF | 190,831 | $149M | Feb 2026 |
Valuation
Market Cap
$62.84B
Enterprise Value
$59.62B
P/E (TTM)
14.70x
Forward P/E
13.20x
PEG Ratio
3.38x
P/B
2.04x
P/S
4.62x
P/FCF
16.23x
EV/EBITDA
10.25x
Shares Out
108.6M
Financials (TTM)
Revenue
$14.34B
Net Income
$4.50B
EBITDA
$5.82B
Free Cash Flow
$4.08B
Op Cash Flow
$4.98B
EPS Basic
$43.07
EPS Diluted
$41.48
EPS Forward
$46.20
Gross Margin
85.4%
Op Margin
24.9%
Net Margin
31.4%
Balance Sheet
Total Assets
$40.56B
Total Liab.
$9.30B
Total Equity
$31.26B
Cash
$8.61B
LT Debt
$1.99B
Book Value/Sh
$298.82
Debt/Equity
0.09x
Current Ratio
4.13
Quick Ratio
3.39
Returns & Growth
ROE
14.1%
ROA
10.8%
ROIC
8.5%
Rev Growth YoY
+1.0%
EPS Growth YoY
+5.3%
Price Returns
2W
-13.8%
1M
-13.1%
3M
-21.4%
6M
-21.2%
12M
+25.4%
Technicals
52W High
$821.11
52W Low
$506.38
50d MA
$680.04
200d MA
$697.07
RSI (14)
47.90
ATR (14)
$15.75
Beta
0.40
Avg Volume
1.2M
Dividends
Div Rate
$3.54
Div Yield
0.5%
Frequency
4
Ex-Div Date
Feb 20, 2026
Analyst Price Targets
Consensus
$864.63
High
$1057.00
Low
$700.00
Median
$873.00
Data updated apr 26, 2026 10:23pm
· Source: financialmodelingprep.com